摘要
Traumatic brain injury represents a major public health issue that affects 1.7 million Americans each year and is a primary contributing factor (30.5%) of all injury-related deaths in the United States. The occurrence of traumatic brain injury is likely underestimated and thus has been termed "a silent epidemic". Exendin-4 is a long-acting glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes mellitus that not only effectively induces glucose-dependent insulin secretion to regulate blood glucose levels but also reduces apoptotic cell death of pancreatic β-cells. Accumulating evidence also supports a neurotrophic and neuroprotective role of glucagon-like peptide-1 in an array of cellular and animal neurodegeneration models. In this study, we evaluated the neuroprotective effects of Exendin-4 using a glutamate toxicity model in vitro and fluid percussion injury in vivo. We found neuroprotective effects of Exendin-4 both in vitro, using markers of cell death, and in vivo, using markers of cognitive function, as assessed by Morris Water Maze. In combination with the reported benefits of ex-4 in other TBI models, these data support repositioning of Exendin-4 as a potential treatment for traumatic brain injury.
| 原文 | 英語 |
|---|---|
| 文章編號 | e82016 |
| 期刊 | PLoS One |
| 卷 | 8 |
| 發行號 | 12 |
| DOIs | |
| 出版狀態 | 已發佈 - 十二月 2 2013 |
指紋
ASJC Scopus subject areas
- Agricultural and Biological Sciences(all)
- Biochemistry, Genetics and Molecular Biology(all)
- Medicine(all)
引用此文
Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. / Eakin, Katharine; Li, Yazhou; Chiang, Yung Hsiao; Hoffer, Barry J.; Rosenheim, Hilary; Greig, Nigel H.; Miller, Jonathan P.
於: PLoS One, 卷 8, 編號 12, e82016, 02.12.2013.研究成果: 雜誌貢獻 › 文章
}
TY - JOUR
T1 - Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats
AU - Eakin, Katharine
AU - Li, Yazhou
AU - Chiang, Yung Hsiao
AU - Hoffer, Barry J.
AU - Rosenheim, Hilary
AU - Greig, Nigel H.
AU - Miller, Jonathan P.
PY - 2013/12/2
Y1 - 2013/12/2
N2 - Traumatic brain injury represents a major public health issue that affects 1.7 million Americans each year and is a primary contributing factor (30.5%) of all injury-related deaths in the United States. The occurrence of traumatic brain injury is likely underestimated and thus has been termed "a silent epidemic". Exendin-4 is a long-acting glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes mellitus that not only effectively induces glucose-dependent insulin secretion to regulate blood glucose levels but also reduces apoptotic cell death of pancreatic β-cells. Accumulating evidence also supports a neurotrophic and neuroprotective role of glucagon-like peptide-1 in an array of cellular and animal neurodegeneration models. In this study, we evaluated the neuroprotective effects of Exendin-4 using a glutamate toxicity model in vitro and fluid percussion injury in vivo. We found neuroprotective effects of Exendin-4 both in vitro, using markers of cell death, and in vivo, using markers of cognitive function, as assessed by Morris Water Maze. In combination with the reported benefits of ex-4 in other TBI models, these data support repositioning of Exendin-4 as a potential treatment for traumatic brain injury.
AB - Traumatic brain injury represents a major public health issue that affects 1.7 million Americans each year and is a primary contributing factor (30.5%) of all injury-related deaths in the United States. The occurrence of traumatic brain injury is likely underestimated and thus has been termed "a silent epidemic". Exendin-4 is a long-acting glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes mellitus that not only effectively induces glucose-dependent insulin secretion to regulate blood glucose levels but also reduces apoptotic cell death of pancreatic β-cells. Accumulating evidence also supports a neurotrophic and neuroprotective role of glucagon-like peptide-1 in an array of cellular and animal neurodegeneration models. In this study, we evaluated the neuroprotective effects of Exendin-4 using a glutamate toxicity model in vitro and fluid percussion injury in vivo. We found neuroprotective effects of Exendin-4 both in vitro, using markers of cell death, and in vivo, using markers of cognitive function, as assessed by Morris Water Maze. In combination with the reported benefits of ex-4 in other TBI models, these data support repositioning of Exendin-4 as a potential treatment for traumatic brain injury.
UR - http://www.scopus.com/inward/record.url?scp=84891464127&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891464127&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0082016
DO - 10.1371/journal.pone.0082016
M3 - Article
C2 - 24312624
AN - SCOPUS:84891464127
VL - 8
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 12
M1 - e82016
ER -